March 6, 2026 · 12 min read

How GLP-1 Medications Affect Endurance Training: What the Science Actually Says

Over 15 million Americans now use semaglutide or tirzepatide. If you're a cyclist, runner, or triathlete on one of these medications, your training data is lying to you — unless you know what to look for.

The Hidden Problem

You're 60km into a long ride. Your power numbers are where they should be, but something feels off. Your heart rate is 8 beats higher than usual at the same effort. Recovery between intervals takes longer. You finish the ride, and your Whoop recovery score the next morning makes no sense.

If you're on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), this isn't a bad day. It's pharmacology. And your training tools have no idea it's happening.

The problem isn't the medication. The problem is that every training platform on the market was built for athletes who aren't on medication. Your power zones, recovery predictions, and training load calculations all assume a metabolic baseline that GLP-1 therapy fundamentally alters.

1. Glycogen: Your Engine Runs Differently Now

GLP-1 receptor agonists enhance insulin-mediated glucose transport into muscle cells, which theoretically accelerates glycogen replenishment after exercise.^[1] Sounds beneficial. But there's a catch.

The same medications suppress appetite and delay gastric emptying — significantly. For endurance athletes who depend on mid-ride fueling, this creates a practical crisis: you can't eat enough, fast enough, to sustain glycogen stores during long efforts.^[2]

What this means for your rides

• Bonking earlier — Reduced carbohydrate intake limits glycogen stores, particularly on rides beyond 90 minutes
• Fueling timing shifts — Gastric emptying delays of 30-60 minutes mean gels and bars need to be consumed significantly earlier than you're used to
• Recovery window changes — Post-ride glycogen repletion dynamics are altered; the traditional "30-minute window" may need to extend to 60-90 minutes

2. Heart Rate: Your Zones Are Wrong

This is the finding that should concern every endurance athlete on GLP-1 therapy. A 2024 study published in the American Journal of Physiology demonstrated that GLP-1 receptor agonist therapy leads to significant increases in resting heart rate, mediated by reductions in heart rate variability.^[4]

Research from Oxford shows that GLP-1 directly affects sinus node firing through calcium clock signaling changes — this isn't a fitness effect, it's a pharmacological one.^[5] Your Whoop or Oura has no way to distinguish between "poor recovery" and "medication-induced HRV suppression."

A 32-year-old athlete with insulin resistance began semaglutide for weight loss. Her resting pulse increased from 54 to 70 bpm. Within normal limits — but she noted subtle changes in recovery time that her tracking apps couldn't explain.^[6]

3. Lean Mass: The Silent Performance Thief

This is the most well-documented risk. Clinical trials consistently show that 20-50% of weight lost on GLP-1 medications comes from lean body mass.^[3] A University of Alberta research team found that participants lost 10% or more of their muscle mass over 68-72 week trials — equivalent to roughly 20 years of age-related muscle loss compressed into 16 months.^[7]

For endurance athletes specifically

• Power-to-weight ratio — Improves initially (less weight), but plateaus as muscle loss erodes absolute power
• Sprint capacity — Fast-twitch fiber loss affects climbs, surges, and race finishes
• Injury risk — Musculoskeletal concerns increase as supporting muscle diminishes^[8]

The solution is clear from the literature: resistance training combined with adequate protein intake (1.6-2.2g/kg/day) significantly mitigates lean mass loss.^[9] But how many cyclists or runners actually do enough strength work? And how do you know if you're losing muscle when your scale just says "lighter"?

4. VO2max: Weight Loss ≠ Fitness Gains

Here's the counterintuitive finding. Researchers at the University of Virginia reviewed the literature and concluded that while GLP-1 therapy clearly reduces body weight and fat, these benefits "don't translate into significant improvements in VO2max" or overall cardiorespiratory fitness.^[10]

For athletes, this is critical. Losing 10kg should theoretically make you faster uphill. But if 3-4kg of that is muscle, your power output drops proportionally. The net performance effect can be zero — or negative.

5. WADA Is Watching

Since January 1, 2026, WADA has added both semaglutide and tirzepatide markers to its Monitoring Program.^[11] These medications aren't currently prohibited, but WADA is actively collecting data on their prevalence in competitive sport.

For age-group athletes, this isn't an immediate concern. But it signals that the sports science community recognizes these drugs alter performance-relevant physiology in ways that aren't fully understood yet.

6. What You Should Actually Do

If you're an endurance athlete on GLP-1 therapy, the evidence points to five concrete adjustments:

1. Retest your zones. Your HR zones from before medication are wrong. Do a new threshold test 4-6 weeks after reaching your maintenance dose.
2. Shift fueling earlier. Eat smaller, easily digestible portions 60-90 minutes before your usual timing. Liquid calories (maltodextrin drinks) bypass some gastric emptying delays.
3. Prioritize strength training. Two sessions per week minimum. Focus on compound movements. This is non-negotiable for preserving lean mass.
4. Track protein intake. Aim for 1.6-2.2g/kg/day. Most GLP-1 users undereat protein due to appetite suppression.
5. Interpret recovery data differently. Your HRV will read lower. Your resting HR will read higher. This is the medication, not overtraining. Build a new baseline after 8-12 weeks on a stable dose.

References

1. Xiao C, et al. "GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway." Biochimica et Biophysica Acta, 2022. doi:10.1016/j.bbadis.2022.166426
2. Dietitian Approved. "GLP-1s and Endurance Performance: What Athletes Need to Know." 2025. dietitianapproved.com
3. Sword Health. "GLP-1 Muscle Loss Comparison: Ozempic vs Wegovy vs Mounjaro vs Zepbound." 2025. swordhealth.com
4. Heart and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference. Am J Physiol Heart Circ Physiol, 2024. PMID: 39705534
5. Baggio LL, et al. "Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node." Cardiovascular Research, 2024. doi:10.1093/cvr/cvae120
6. Tashko G, MD. "GLP-1 Agonists and Heart Rate: Prevalence and Clinical Significance." 2025. gertitashkomd.com
7. CBC News. "University of Alberta researchers raise concerns over muscle loss with popular obesity drugs." 2024. cbc.ca
8. The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care. PMC, 2025. PMC12325148
9. ACE Fitness. "GLP-1s and Lean Mass: What the Research Shows." June 2025. acefitness.org
10. University of Virginia. "UVA researchers find weight-loss drugs don't substantially improve fitness." 2025. news.virginia.edu
11. WADA. "2026 Monitoring Program." September 2025. wada-ama.org
12. ResearchGate. Tirzepatide in Sport: A Comprehensive Review of its Metabolic Impacts and Potential Applications for Athletes. 2025. researchgate.net

Velometric Research

Built by endurance athletes who needed more than existing platforms could offer. velometric.io